| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | procarbazine | CTRPv2 | pan-cancer | AAC | -0.0034 | 0.9 |
| mRNA | AT-406 | CTRPv2 | pan-cancer | AAC | -0.004 | 0.9 |
| mRNA | Irinotecan | FIMM | pan-cancer | AAC | -0.011 | 0.9 |
| mRNA | Cytarabine | FIMM | pan-cancer | AAC | -0.014 | 0.9 |
| mRNA | Topotecan | FIMM | pan-cancer | AAC | 0.0097 | 0.9 |
| mRNA | BRD-K16130065 | CTRPv2 | pan-cancer | AAC | -0.006 | 0.9 |
| mRNA | Nilotinib | FIMM | pan-cancer | AAC | -0.016 | 0.9 |
| mRNA | CIL55A | CTRPv2 | pan-cancer | AAC | -0.0039 | 0.9 |
| mRNA | navitoclax:sorafenib (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0026 | 0.9 |
| mRNA | PLX4720 | CCLE | pan-cancer | AAC | 0.0032 | 0.9 |